Status:
UNKNOWN
S-amlodipine in Essential HypertensIon and Assessment of Blood Pressure Targets Achievement
Lead Sponsor:
Hanlim Pharm. Co., Ltd.
Conditions:
Essential Hypertension
Eligibility:
All Genders
19+ years
Brief Summary
Evaluate the ratio(%) of patients whose blood pressure measured at 6 months from the baseline was confirmed to be within the target blood pressure range according to the 2022 hypertension treatment gu...
Detailed Description
Primary purpose: Evaluate the ratio(%) of patients whose blood pressure measured at 6 months from the baseline was confirmed to be within the target blood pressure range according to the 2022 hyperte...
Eligibility Criteria
Inclusion
- Adults over 19 years of age
- A person who was diagnosed with essential hypertension at the time of participation in the study or was previously diagnosed with essential hypertension and is taking antihypertensive drugs for treatment (Essential hypertension: Systolic blood pressure greater than 140mmHg or diastolic blood pressure greater than 90mmHg)
- A person whose prescription for the study drug under study was confirmed at the time of participation in the study
- A person who voluntarily decided to participate in this observational study and gave written consent to the consent form
Exclusion
- Patients who are contraindicated in administration of study drug according to the permission
- Patients with a history of hypersensitivity to the study drug or its components or other dihydropyridine-based drugs
- Women who are pregnant or may be pregnant, and women who are lactating
- Patients with shock (including cardiogenic shock), severe aortic valve stenosis, unstable angina, within 1 month after myocardial infarction, severe hypotension, severe liver dysfunction
- Patients who are inappropriate to participate in the study in the judgement of the investigator
Key Trial Info
Start Date :
February 22 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 25 2025
Estimated Enrollment :
5000 Patients enrolled
Trial Details
Trial ID
NCT06130124
Start Date
February 22 2023
End Date
July 25 2025
Last Update
November 14 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bundang Seoul University Hospital
Seongnam-si, Gyeonggi-do, South Korea, 13620